Laden.... Wacht alsjeblieft even.
Bedrijfsprofiel
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Bron:
Cofisem
-
laatste update:
17 Nov 2024
Bestuurders
| Chief Executive Officer | Lyn Rees | ||||
| Chief Financial Officer | Steve Gibson | ||||
| Company Secretary | Steve Gibson | ||||
| Bron: Cofisem - laatste update: 17 Nov 2024 | |||||
Kerncijfers
| Millenium | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Net sales | 11.579 | 21.040 | 95.780 | 277.204 | 11.468 |
| Income from ordinary activities | 11.579 | 21.040 | 95.780 | 277.204 | 11.468 |
| Operating income | -29.516 | -23.393 | -7.795 | 167.441 | -1.556 |
| Cost of financial indebtedness net | -53 | -321 | -147 | 1.601 | 0 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | -492 | -3.529 | -2.330 | ||
| Net income | -28.292 | -25.730 | -9.728 | 132.423 | -5.749 |
| Net income (Group share) | -28.292 | -25.730 | -9.728 | 132.423 | -5.749 |
| Fiscal year end | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | GBP - thousands | GBP - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Bron: Cofisem - laatste update: 17 Nov 2024 | |||||
Aandeelhoudersinformatie
Adres
Novacyt
13 Avenue Morane Saulnier
FR-78140
Vélizy-Villacoublay
France
Telefoonnummer:
+33 (0)1 39 46 51 04
Fax:
+33 (0)1 30 70 05 32
Bron:
Cofisem
-
laatste update:
17 Nov 2024